Patent Title: Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
Patent Number: 12678408
Company: Gilead Sciences, Inc.
Inventors: Joanna M. Koziara, Scott McCallister
Antiretroviral therapies for human immunodeficiency virus (HIV) treatment and pre-exposure prophylaxis require precise drug combinations that ensure high clinical efficacy, long-term safety, and high patient adherence. Addressing these crucial therapeutic requirements, Gilead Sciences, Inc. has advanced solid oral dosage formulation technology. Their newly patented pharmaceutical formulation combines tenofovir alafenamide and emtricitabine into an optimized fixed-dose tablet. By significantly reducing total excipient volume while maintaining chemical stability, this formulation enables a smaller tablet size that enhances patient compliance without sacrificing therapeutic potency.
Why This Invention is Innovative
This patent introduces a specialized solid oral dosage form that solves a persistent challenge in combination antiretroviral therapy: drug degradation and oversized oral tablets. Combining multiple active pharmaceutical ingredients into a single tablet frequently leads to chemical instability, reduced shelf life, or large pill dimensions that are difficult for patients to swallow consistently. Gilead’s formulation overcomes this by establishing a precise concentration window, utilizing tenofovir alafenamide hemifumarate at 7 percent to 9 percent by weight alongside emtricitabine while minimizing necessary filler excipients. This formulation strategy effectively limits degradation product formation over time, ensuring maximum drug potency and patient safety while producing a much smaller, easier-to-swallow daily dose for patients on long-term antiretroviral regimens.
August 2026 Patent of the Month for the Pharma-Medical-Devices-Healthcare Industry
Granted in July 2026, this formulation advancement has been rightfully awarded the Patent of the Month for the pharma-medical-devices-healthcare industry for August 2026. Global public health strategies against HIV rely heavily on fixed-dose combination therapies that promote long-term treatment compliance. Gilead Sciences, Inc. has successfully refined one of the world’s most essential antiretroviral combinations to achieve superior physical acceptability and chemical stability. Recognizing this patent highlights the critical role that formulation science plays in modern healthcare, demonstrating that optimizing pill burden and manufacturing stability is just as vital as target discovery when delivering life-saving therapies to global populations.
Practical Applications and R&D Tax Credit Eligibility in the USA
The practical applications of this patent involve advanced pharmaceutical chemistry, formulation engineering, and analytical stability testing, making the underlying development activities highly eligible for the Research and Development (R&D) Tax Credit in the United States. To qualify for this federal tax incentive, a project must satisfy a four-part test: the work must be technological in nature, serve a permitted purpose, seek to eliminate technical uncertainty, and employ a systematic process of experimentation. Formulating a stable dual-drug tablet requires pharmaceutical scientists to systematically evaluate excipient matrices, conduct stress testing under varying thermal and humidity conditions to measure degradation rates, and execute dissolution testing to confirm bioequivalence. By thoroughly documenting these laboratory trials, batch test results, and analytical methods used to optimize active ingredient ratios, pharmaceutical and biotechnology companies engaging in similar drug formulation research can successfully claim the R&D tax credit to offset their technical development costs.
